
Saraswati Sukumar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5103706/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 2010, 464, 1071-1076.	13.7	4,648
2	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	6.0	3,049
3	Molecular Definition of Breast Tumor Heterogeneity. Cancer Cell, 2007, 11, 259-273.	7.7	1,273
4	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nature Genetics, 2011, 43, 621-629.	9.4	1,080
5	Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature, 1985, 315, 382-385.	13.7	872
6	Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature, 1983, 306, 658-661.	13.7	736
7	Analysis of human transcriptomes. Nature Genetics, 1999, 23, 387-388.	9.4	719
8	The Hox genes and their roles in oncogenesis. Nature Reviews Cancer, 2010, 10, 361-371.	12.8	685
9	Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature, 2000, 405, 974-978.	13.7	451
10	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene, 2003, 22, 2021-2033.	2.6	415
11	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet, The, 2001, 357, 1335-1336.	6.3	324
12	Targeted nanopore sequencing with Cas9-guided adapter ligation. Nature Biotechnology, 2020, 38, 433-438.	9.4	286
13	Hypermethylation of 14-3-3 i_f (stratifin) is an early event in breast cancer. Oncogene, 2001, 20, 3348-3353.	2.6	284
14	Modeling precision treatment of breast cancer. Genome Biology, 2013, 14, R110.	13.9	264
15	Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Research, 2012, 72, 1384-1394.	0.4	261
16	Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Cell, 2010, 143, 84-98.	13.5	254
17	DNA methylation ofRASSF1A, HIN-1, RAR-?, Cyclin D2 andTwist inin situ and invasive lobular breast carcinoma. International Journal of Cancer, 2003, 107, 970-975.	2.3	242
18	Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer. Cancer Research, 2004, 64, 4442-4452.	0.4	241

#	Article	IF	CITATIONS
19	Clostridium perfringens Enterotoxin Elicits Rapid and Specific Cytolysis of Breast Carcinoma Cells Mediated through Tight Junction Proteins Claudin 3 and 4. American Journal of Pathology, 2004, 164, 1627-1633.	1.9	236
20	Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14076-14081.	3.3	210
21	The Mammalian Ortholog of <i>Drosophila</i> MOF That Acetylates Histone H4 Lysine 16 Is Essential for Embryogenesis and Oncogenesis. Molecular and Cellular Biology, 2008, 28, 397-409.	1.1	194
22	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. Clinical Cancer Research, 2008, 14, 1938-1946.	3.2	193
23	Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 2000, 19, 1556-1563.	2.6	188
24	Alterations in Vascular Gene Expression in Invasive Breast Carcinoma. Cancer Research, 2004, 64, 7857-7866.	0.4	183
25	Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. Cancer Research, 2011, 71, 6195-6207.	0.4	179
26	RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer. Cancer Research, 2006, 66, 6512-6520.	0.4	177
27	Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment. Clinical Cancer Research, 2013, 19, 1651-1659.	3.2	175
28	HOXB7, a Homeodomain Protein, Is Overexpressed in Breast Cancer and Confers Epithelial-Mesenchymal Transition. Cancer Research, 2006, 66, 9527-9534.	0.4	171
29	Genetic and Phenotypic Diversity in Breast Tumor Metastases. Cancer Research, 2014, 74, 1338-1348.	0.4	161
30	Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer, 2005, 116, 920-924.	2.3	160
31	Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nature Communications, 2014, 5, 4715.	5.8	154
32	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research, 2014, 74, 2160-2170.	0.4	149
33	Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole. Cancer Research, 2011, 71, 1893-1903.	0.4	147
34	Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung. Clinical Cancer Research, 2004, 10, 3104-3109.	3.2	129
35	HOXA5-Induced Apoptosis in Breast Cancer Cells Is Mediated by Caspases 2 and 8. Molecular and Cellular Biology, 2004, 24, 924-935.	1.1	129
36	Targeting Clutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical Cancer Research, 2015, 21, 3263-3273.	3.2	129

#	Article	IF	CITATIONS
37	Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. Clinical Cancer Research, 2006, 12, 3306-3310.	3.2	122
38	SLITs Suppress Tumor Growth <i>In vivo</i> by Silencing <i>Sdf1/Cxcr4</i> within Breast Epithelium. Cancer Research, 2008, 68, 7819-7827.	0.4	117
39	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. Journal of Clinical Oncology, 2017, 35, 751-758.	0.8	110
40	Hypermethylation in Histologically Distinct Classes of Breast Cancer. Clinical Cancer Research, 2004, 10, 5998-6005.	3.2	109
41	Nanoparticle interactions with immune cells dominate tumor retention and induce T cell–mediated tumor suppression in models of breast cancer. Science Advances, 2020, 6, eaay1601.	4.7	107
42	HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells. PLoS ONE, 2013, 8, e63419.	1.1	106
43	Estrogen Receptor/Progesterone Receptor-Negative Breast Cancers of Young African-American Women Have a Higher Frequency of Methylation of Multiple Genes than Those of Caucasian Women1. Clinical Cancer Research, 2004, 10, 2052-2057.	3.2	103
44	Epigenetic Regulation of Cell Type–Specific Expression Patterns in the Human Mammary Epithelium. PLoS Genetics, 2011, 7, e1001369.	1.5	96
45	Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chemical Science, 2015, 6, 3906-3914.	3.7	96
46	A biologic scaffold–associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. Science Translational Medicine, 2019, 11, .	5.8	96
47	Collagen I fiber density increases in lymph node positive breast cancers: pilot study. Journal of Biomedical Optics, 2012, 17, 116017.	1.4	95
48	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	3.3	95
49	Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid. Clinical Cancer Research, 2005, 11, 8312-8320.	3.2	93
50	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 300-319.	3.3	89
51	DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biology and Therapy, 2010, 10, 44-53.	1.5	85
52	Ductal Access for Prevention and Therapy of Mammary Tumors. Cancer Research, 2006, 66, 638-645.	0.4	84
53	Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biology and Therapy, 2006, 5, 281-286.	1.5	81
54	Epigenetic Inactivation of the Potential Tumor Suppressor Gene <i>FOXF1</i> in Breast Cancer. Cancer Research, 2010, 70, 6047-6058.	0.4	81

#	Article	IF	CITATIONS
55	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ERα and Inducing IL-6 Expression. Cancer Research, 2013, 73, 5449-5458.	0.4	80
56	A Role for the HOXB7 Homeodomain Protein in DNA Repair. Cancer Research, 2007, 67, 1527-1535.	0.4	79
57	Role of homeobox genes in normal mammary gland development and breast tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 159-175.	1.0	73
58	Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor Characteristics. Cell Stem Cell, 2013, 13, 117-130.	5.2	72
59	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications, 2014, 5, 4961.	5.8	72
60	HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discovery, 2015, 5, 944-959.	7.7	72
61	Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 2017, 7, 1062-1071.	4.6	71
62	HOXA5 Regulates Expression of the Progesterone Receptor. Journal of Biological Chemistry, 2000, 275, 26551-26555.	1.6	68
63	Clostridium perfringens Enterotoxin as a Novel-Targeted Therapeutic for Brain Metastasis. Cancer Research, 2007, 67, 7977-7982.	0.4	67
64	MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Modern Pathology, 2012, 25, 378-387.	2.9	67
65	<i>HOXA5</i> Acts Directly Downstream of Retinoic Acid Receptor β and Contributes to Retinoic Acid–Induced Apoptosis and Growth Inhibition. Cancer Research, 2007, 67, 8007-8013.	0.4	66
66	Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Research and Treatment, 2010, 123, 701-708.	1.1	66
67	Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer. Science Translational Medicine, 2011, 3, 106ra108.	5.8	66
68	Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. Cancer Research, 2006, 66, 9829-9836.	0.4	62
69	Hoxb7 Inhibits Transgenic HER-2/neu–Induced Mouse Mammary Tumor Onset but Promotes Progression and Lung Metastasis. Cancer Research, 2008, 68, 3637-3644.	0.4	61
70	Somatic mutations in the notch, NFâ€KB, PIK3CA, and hedgehog pathways in human breast cancers. Genes Chromosomes and Cancer, 2012, 51, 480-489.	1.5	58
71	Methylation Profiling of Benign and Malignant Breast Lesions and Its Application to Cytopathology. Modern Pathology, 2003, 16, 1095-1101.	2.9	57
72	Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. Cell Reports, 2015, 11, 1549-1563.	2.9	57

#	Article	IF	CITATIONS
73	The Role of WT1 in Oncogenesis: Tumor Suppressor or Oncogene?. International Journal of Hematology, 2002, 76, 117-126.	0.7	55
74	Altered antisense-to-sense transcript ratios in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2820-2824.	3.3	54
75	HOXB7 Promotes Malignant Progression by Activating the TGFÎ ² Signaling Pathway. Cancer Research, 2015, 75, 709-719.	0.4	54
76	Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis, 2012, 33, 2242-2249.	1.3	53
77	Telomerase Activity and Prognosis in Primary Breast Cancers. Journal of Clinical Oncology, 1999, 17, 3075-3081.	0.8	52
78	HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Research, 2016, 76, 4443-4456.	0.4	52
79	HOX Genes — Emerging Stars in Cancer. Cancer Biology and Therapy, 2003, 2, 524-525.	1.5	49
80	Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. International Journal of Cancer, 2012, 131, E1166-72.	2.3	49
81	Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB Journal, 1999, 13, 1047-1054.	0.2	47
82	Identification of Transcriptional Targets of HOXA5. Journal of Biological Chemistry, 2005, 280, 19373-19380.	1.6	45
83	Methylated genes in breast cancer. Cancer Biology and Therapy, 2011, 11, 853-865.	1.5	44
84	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget, 2015, 6, 29143-29160.	0.8	44
85	Hypermethylated Genes as Biomarkers of Cancer in Women with Pathologic Nipple Discharge. Clinical Cancer Research, 2009, 15, 3802-3811.	3.2	42
86	The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget, 2017, 8, 2971-2983.	0.8	42
87	Frequent activation of the Ki-ras oncogene at codon 12 inN-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Molecular Carcinogenesis, 1991, 4, 362-368.	1.3	41
88	Benzoylphenylurea Sulfur Analogues with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2006, 49, 2357-2360.	2.9	41
89	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 2013-2024.	0.4	40
90	Cyclin E Is a Target of WT1 Transcriptional Repression. Journal of Biological Chemistry, 2002, 277, 19627-19632.	1.6	39

6

#	Article	IF	CITATIONS
91	Applications of telomerase research in the fight against cancer. Trends in Molecular Medicine, 1999, 5, 114-122.	2.6	37
92	Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells. Journal of Biological Chemistry, 2006, 281, 19055-19063.	1.6	37
93	Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications, 2019, 10, 4182.	5.8	37
94	MethySYBR, a Novel Quantitative PCR Assay for the Dual Analysis of DNA Methylation and CpG Methylation Density. Journal of Molecular Diagnostics, 2009, 11, 400-414.	1.2	36
95	A Self-Folding Hydrogel <i>In Vitro</i> Model for Ductal Carcinoma. Tissue Engineering - Part C: Methods, 2016, 22, 398-407.	1.1	36
96	Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Research, 2010, 20, 1730-1739.	2.4	35
97	Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biology and Therapy, 2010, 9, 1017-1024.	1.5	34
98	Proteomic characterization of Her2/neuâ€overexpressing breast cancer cells. Proteomics, 2010, 10, 3800-3810.	1.3	32
99	The p53–p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cellular Signalling, 2012, 24, 316-324.	1.7	32
100	HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188450.	3.3	32
101	Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecologic Oncology, 2010, 118, 176-181.	0.6	30
102	The Widening Sphere of Influence of HOXB7 in Solid Tumors. Cancer Research, 2016, 76, 2857-2862.	0.4	30
103	The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cellular Signalling, 2016, 28, 1502-1519.	1.7	29
104	Two-color quantitative multiplex methylation-specific PCR. BioTechniques, 2006, 40, 210-219.	0.8	28
105	Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells. Cancer Biology and Therapy, 2003, 2, 259-263.	1.5	27
106	The Notch Pathway Inhibits TGFβ Signaling in Breast Cancer through HEYL-Mediated Crosstalk. Cancer Research, 2014, 74, 6509-6518.	0.4	27
107	Of Snail, mice, and women. Cancer Cell, 2005, 8, 173-174.	7.7	26
108	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4008-4016.	3.2	26

#	Article	IF	CITATIONS
109	Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation. Molecular Cancer Therapeutics, 2015, 14, 2390-2400.	1.9	26
110	Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. Molecular and Cellular Proteomics, 2015, 14, 2887-2900.	2.5	26
111	Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biology and Therapy, 2008, 7, 1398-1406.	1.5	25
112	Inhibitors of <scp>STAT</scp> 3, βâ€catenin, and <scp>IGF</scp> â€1R sensitize mouse <scp>PIK</scp> 3 <scp>CA</scp> â€mutant breast cancer to <scp>PI</scp> 3K inhibitors. Molecular Oncology, 2017, 11, 552-566.	2.1	25
113	Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget, 2016, 7, 33306-33315.	0.8	25
114	Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability. Oncogene, 1998, 17, 2137-2142.	2.6	24
115	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	0.8	24
116	A comparative study of korean with caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in korean women. Cancer Biology and Therapy, 2007, 6, 1114-1120.	1.5	23
117	Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity. Cancer Investigation, 2012, 30, 119-125.	0.6	23
118	Tissue Specific DNA Methylation in Normal Human Breast Epithelium and in Breast Cancer. PLoS ONE, 2014, 9, e91805.	1.1	23
119	Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays. Angewandte Chemie - International Edition, 2019, 58, 17158-17162.	7.2	22
120	Differential Effects of Wilms Tumor WT1 Splice Variants on the Insulin Receptor Promoter. Biochemical and Molecular Medicine, 1997, 62, 139-150.	1.5	21
121	Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas. Cancer Letters, 2004, 210, 239-244.	3.2	21
122	PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2009, 75, 499-508.	1.5	21
123	Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. Breast Cancer Research and Treatment, 2012, 135, 201-208.	1.1	21
124	DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical Cancer Research, 2019, 25, 6357-6367.	3.2	21
125	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. PLoS ONE, 2014, 9, e105545.	1.1	20
126	Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese. Cancer Biology and Therapy, 2006, 5, 544-548.	1.5	19

#	Article	IF	CITATIONS
127	Multiple roles of HOX proteins in Metastasis: Let me count the ways. Cancer and Metastasis Reviews, 2020, 39, 661-679.	2.7	19
128	Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. JCI Insight, 2017, 2, .	2.3	19
129	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Research, 2018, 20, 145.	2.2	18
130	Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 1006-1013.	1.5	17
131	Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. Experimental and Molecular Pathology, 2013, 94, 262-269.	0.9	17
132	Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study. Carcinogenesis, 2019, 40, 903-913.	1.3	17
133	Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clinical Proteomics, 2018, 15, 21.	1.1	15
134	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 3.	2.3	15
135	Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Research and Treatment, 2018, 167, 107-116.	1.1	14
136	Absence of TSG101 transcript abnormalities in human cancers. Oncogene, 1998, 16, 2815-2818.	2.6	12
137	Epigenetic Biomarkers and Breast Cancer: Cause for Optimism. Clinical Cancer Research, 2006, 12, 6591-6593.	3.2	12
138	ADP Ribosylation by PARP-1 Suppresses HOXB7 Transcriptional Activity. PLoS ONE, 2012, 7, e40644.	1.1	12
139	A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers. Cancer Biology and Therapy, 2014, 15, 1593-1599.	1.5	12
140	HOX genes: Major actors in resistance to selective endocrine response modifiers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 105-110.	3.3	12
141	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. Clinical Epigenetics, 2021, 13, 104.	1.8	10
142	Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 35-42.	1.4	9
143	Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. Cancer Prevention Research, 2016, 9, 673-682.	0.7	9
144	Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay. Methods in Molecular Biology, 2018, 1708, 473-496.	0.4	9

#	Article	IF	CITATIONS
145	A pivotal role for HOXB7 protein in endocrine resistant breast cancer. Oncoscience, 2015, 2, 917-919.	0.9	9
146	Intraductal therapy for the prevention of breast cancer. Current Opinion in Investigational Drugs, 2010, 11, 646-52.	2.3	9
147	Validation of a low-cost, carbon dioxide-based cryoablation system for percutaneous tumor ablation. PLoS ONE, 2019, 14, e0207107.	1.1	8
148	Intraductal Therapy in Breast Cancer: Current Status and Future Prospective. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 133-143.	1.0	8
149	Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
150	Novel agents for chemoprevention, screening methods, and sampling issues. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 75-89.	1.0	7
151	BRCA1: linking HOX to breast cancer suppression. Breast Cancer Research, 2010, 12, 306.	2.2	7
152	Eradication of microscopic hepatic metastases by active specific immunization. Cancer Immunology, Immunotherapy, 1983, 14, 151-154.	2.0	6
153	Big Punches Come in Nanosizes for Chemoprevention. Cancer Prevention Research, 2013, 6, 1007-1010.	0.7	6
154	Characteristics and antitumor activity of polysorbate 80 curcumin micelles preparation by cloud point cooling. Journal of Drug Delivery Science and Technology, 2020, 59, 101871.	1.4	6
155	HEYL Regulates Neoangiogenesis Through Overexpression in Both Breast Tumor Epithelium and Endothelium. Frontiers in Oncology, 2020, 10, 581459.	1.3	6
156	Intraductal administration of N-methyl-N-nitrosourea as a novel rodent mammary tumor model. Annals of Translational Medicine, 2021, 9, 576-576.	0.7	6
157	Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer. Npj Breast Cancer, 2021, 7, 89.	2.3	6
158	CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. Oncogene, 2021, 40, 5752-5763.	2.6	6
159	Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment. Breast Cancer Research, 2014, 16, 306.	2.2	5
160	High performance methylated DNA markers for detection of colon adenocarcinoma. Clinical Epigenetics, 2021, 13, 218.	1.8	5
161	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. Cancer Research Communications, 2022, 2, 391-401.	0.7	5
162	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. ACS Applied Materials & Interfaces, 2022, 14, 24113-24121.	4.0	5

#	Article	IF	CITATIONS
163	Active specific immunotherapy of guinea pigs with visceral tumor implants. Cancer Immunology, Immunotherapy, 1982, 12, 273.	2.0	4
164	Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. Cancer Prevention Research, 2018, 11, 557-568.	0.7	3
165	Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells. Cancers, 2020, 12, 2367.	1.7	3
166	Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression. Cancers, 2022, 14, 1303.	1.7	2
167	Coupling the Transcriptional Regulatory Action of Brn-3b to the Cell Cycle Clock. Cancer Biology and Therapy, 2004, 3, 324-325.	1.5	1
168	ETS genes in breast cancer: A step in the right direction. Cancer Biology and Therapy, 2007, 6, 83-84.	1.5	1
169	Clonal selection in tamoxifen resistance. Cancer Biology and Therapy, 2010, 9, 725-727.	1.5	1
170	Unpredicted central inversion in a sgRNA flanked by inverted repeats. Molecular Biology Reports, 2020, 47, 6375-6378.	1.0	1
171	A specific vaccine effective against stage I and stage II malignant disease in guinea pigs effect of variations in preparations and storage. Cancer Immunology, Immunotherapy, 1982, 14, 92-5.	2.0	0
172	A PET rat model for assessing the effectiveness of new chemotherapies. Cancer Biology and Therapy, 2008, 7, 538-539.	1.5	0
173	Abstract P5-08-03: Intraductal administration of a Transferrin Receptor-directed immunotoxin eliminates ductal carcinoma in situ in preclinical mammary in-duct (MIND) models of breast cancer. Cancer Research, 2022, 82, P5-08-03-P5-08-03.	0.4	0